Catalyst
Slingshot members are tracking this event:
CRISPR and Casebia by Bayer (BAYRY) obtain rights to MaxCyte's cell engineering platform to create therapies for hemoglobin disorders and immunodeficiency
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 14, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Immunodeficiency, Hemoglobin, Maxcyte
